Abstract Introduction The average medication adherence (MA) among patients in developed countries living with a chronic disease is estimated to be roughly 50%.(1) Non-adherence is multi-factorial, owing to socio-economic and clinical factors, as well as arguably the most important factor, patients’ health beliefs and experiences. Patient Reported Outcome Measures (PROMs) are often uni-dimensional in their assessment of drivers of MA. This study has evaluated a novel PROM as part of a wider international research initiative focused on Type 2 Diabetes (T2D) which assesses four key factors of MA referred to as Social (S), Psychological (P), Usage (U) and Rationale (R), in short SPUR®. Aim To compare the validity of SPUR® against previously validated PROMs in patients with T2D. Methods This South London cross-sectional study surveyed adult participants with a confirmed diagnosis of T2D prescribed a minimum of one anti-hyperglycaemic medicine. Surveys were administered face-to-face by community pharmacists using a convenience sampling method based on interactions with pharmacy patients. The survey consisted of questions relating to socio-demographic and clinical data, the SPUR® tool and three previously validated PROMs (BeMQ-General®, MARS-10® and BeMQ-Specific®) as comparators to evaluate factors P, U and R respectively. The Medication Possession Ratio (MPR), a measure of a patient’s pill count in a given time period, was used as an objective comparator of adherence. Pearson’s correlation coefficients (r) were calculated to determine the strength of association between the validated PROMs and SPUR®, with T tests used as a measure of significance (p=<0.05) as an evaluation of validity for SPUR®. Results The survey response rate was 21.6% (n=149/690). The modal age range for participants was 60–69 years of age (40.1%, n=60). Participants were predominantly educated to degree level (29.5%, n=44), White (48.3%, n=72) and retired (28.9%, n=43). Overall, 47.6% (n=71) of participants identified as female. Body Mass Index (BMI) data were available for 88.6% (n=132) of the sample with 42.4% (n=56/132) reporting a BMI >30. In ascending order, moderate to strong positive correlations were observed between SPUR® and the comparative PROMs for factors P (r=0.464, p=<0.0001), U (r=0.595, p=<0.0001) and R (r=0.719, p=<0.0001), indicating SPUR® to be a reliable measure of those MA factors. When assessing MA objectively, SPUR® demonstrated the strongest correlation (r=0.281, p=<0.0001) to MPR compared with the validated tools, with MARS-10® as the closest comparator (r=0.266, p=0.001). Despite this, SPUR® did not overestimate MA, 83.8% (n=125) of the sample was identified as adherent based on MPR compared to 53% (n=79) with SPUR®. The latter more closely reflecting HbA1c data which identified 55.4% (n=31/56) as adherent. Conclusion Study strengths include the implementation of validated PROMs and two objective MA measures; however, the study sample size was limited. SPUR® has demonstrated its validity against validated PROMs whilst predicting adherence levels without exaggeration, which is often attributed to crude objective measures such as MPR.(2) SPUR® may therefore holistically identify the multiple factors linked to non-adherence, thus supporting the design of individualised interventions.. Such interventions are deemed by the World Health Organisation as potentially more impactful than developing new treatments.(1)